De Novo device
BIOFIRE Respiratory Panel 2.1 (RP2.1)
Biofire Diagnostics · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision Mar 17, 2021, newest Sep 22, 2026COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
7
Naming "BIOFIRE"
MAUDE reports
653
Brand "BIOFIRE", since 2015
PubMed studies
833
Mentioning "BIOFIRE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BIOFIRE Respiratory Panel 2.1 (RP2.1)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K263054 · Decided Sep 22, 2026 · 21 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "BIOFIRE", any status and sponsor, newest update first.
BioMérieuxNot on our public-company list
NCT07513519 · 800 participants · Start Dec 22, 2025 · Primary completion Apr 30, 2026
Device: SPOTFIRE R/ST Diagnostic Test · For: Acute Respiratory Infections (ARIs)
Sites: Gardendale, Alabama; Hoover, Alabama
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BIOFIRE", and for the whole product code for context.
This brand
653 reports: 595 malfunction, 52 injury, 6 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
- BIOFIRE RP2.1 PANELMalfunction
3002773840-2026-00157 · Received Oct 29, 2026 · Event dated Aug 19, 2026
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF)
Device problem as coded: Manufacturing, Packaging or Shipping Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BIOFIRE"[tiab]. The summary above synthesizes these.
- Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis.
Buss SN, Leber A, Chapin K, et al. · J Clin Microbiol · 2015Evaluation Study, Multicenter Study
- Clinical Evaluation of the BIOFIRE SPOTFIRE Respiratory Panel.
Chan WS, Ho CW, Chan TC, et al. · Viruses · 2024Research Support, Non-U.S. Gov't
- Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study.
Manabe YC, Betz J, Jackson O, et al. · Lancet Infect Dis · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- BioFire® Joint Infection Panel for Samples Other than Synovial Fluid.
Benvenuto N, Di Bella S, Principe L, et al. · Antibiotics (Basel) · 2024
- Real-life Assessment of BioFire FilmArray Pneumonia Panel in Adults Hospitalized With Respiratory Illness.
Falsey AR, Branche AR, Croft DP, et al. · J Infect Dis · 2024Research Support, N.I.H., Extramural
- Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections.
Buchan BW, Windham S, Balada-Llasat JM, et al. · J Clin Microbiol · 2020Research Support, Non-U.S. Gov't
- Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis.
Liborio MP, Harris PNA, Ravi C, et al. · Microorganisms · 2024Review
- Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection.
Murphy CN, Fowler R, Balada-Llasat JM, et al. · J Clin Microbiol · 2020Multicenter Study, Research Support, Non-U.S. Gov't
- BioFire FilmArray respiratory panel RP2.1 for SARS-CoV-2 detection: The pitfalls.
Chang YC, Hsiao CT, Chen WL, et al. · J Infect · 2022Letter, Comment
- BioFire Respiratory Panel for the Detection of Viruses and Bacteria.
Bennett NF, Bissaillon AL · Am Fam Physician · 2023
- Clinical performance evaluation of the BioFire Joint Infection Panel.
Lee RA · J Clin Microbiol · 2024Evaluation Study, Research Support, N.I.H., Intramural
- Multicenter Evaluation of the BioFire Respiratory Panel 2.1 (RP2.1) for Detection of SARS-CoV-2 in Nasopharyngeal Swab Samples.
Berry GJ, Zhen W, Smith E, et al. · J Clin Microbiol · 2022Multicenter Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QOF.
- Xpert Xpress CoV-2/Flu plusCepheid® · 510(k) 2026
- BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel MiniBiofire Diagnostics, LLC · 510(k) 2025
- QIAstat-Dx Respiratory Panel PlusQIAGEN GmbH · 510(k) 2025
- Panther Fusion SARS-CoV-2/Flu A/B/RSV assayHologic, Inc. · 510(k) 2024
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 SystemsRoche Molecular Systems, Inc. · 510(k) 2025
- cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid testRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.